Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results